You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

obinutuzumab

Showing 1 - 25 of 127
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Mar 7, 2022

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Childhood Nephrotic Syndrome Trial (Obinutuzumab, MMF, Prednisone)

Not yet recruiting
  • Childhood Nephrotic Syndrome
  • Obinutuzumab
  • +5 more
  • (no location specified)
Nov 23, 2022

Primary CNS Lymphoma Trial in Stuttgart (Venetoclax, Obinutuzumab)

Terminated
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
Jan 18, 2022

Leukemia, Lymphocytic, Chronic Trial run by the NCI (rhIL-15, Obinutuzumab)

Terminated
Has Results
  • Leukemia
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Mar 11, 2022

Leukemia Trial in Houston (Pirtobrutinib, Obinutuzumab, Venetoclax)

Not yet recruiting
  • Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 7, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

Recruiting
  • Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

Primary Focal Segmental Glomerulosclerosis Trial in Rochester (Obinutuzumab)

Recruiting
  • Primary Focal Segmental Glomerulosclerosis
  • Obinutuzumab
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Dec 13, 2021

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Obinutuzumab
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 20, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Nanjin, Jiangsu, China
    Department of Haematology, the First Affiliated Hospital of Nanj
Apr 12, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)

Recruiting
  • Lymphoma
  • +3 more
  • obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)

Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 13, 2022

Chronic Lymphocytic Leukemia Trial in Boston, Rochester, Durham (Obinutuzumab, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +3 more
Jan 3, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)

Completed
Has Results
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 10, 2021

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

Suspended
  • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
  • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
  • Obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Mantle Cell Lymphoma Trial in Warszawa, Wroclaw (Obinutuzumab)

Terminated
  • Mantle Cell Lymphoma
  • Obinutuzumab
  • Warszawa, Poland
  • +1 more
Dec 23, 2021

Lymphoma Trial in China (Obinutuzumab, Glofitamab, Tocilizumab)

Recruiting
  • Lymphoma
  • Obinutuzumab
  • +2 more
  • Beijing, China
  • +6 more
Aug 4, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Apr 7, 2022

Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis Trial in Boston, Rochester, Philadelphia

Not yet recruiting
  • Granulomatosis With Polyangiitis
  • +2 more
  • Boston, Massachusetts
  • +2 more
Aug 2, 2022

Chronic Lymphocytic Leukemia Trial in Germany (Obinutuzumab, Venetoclax, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Obinutuzumab
  • +2 more
  • Bad Saarow, Germany
  • +29 more
May 4, 2022

Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Bcl-2 Inhibitor GDC-0199
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Oct 29, 2021